Reta Passes Another Trial

6 replies7 peopleMar 19, 2026☆ Follow

Summary

retatrutide trial results and status of similar triple agonist UBT251

The thread discusses retatrutide clearing an early late-stage diabetes trial and notes the company views it as a key future product after existing treatments. Participants mention UBT251 as the competing triple agonist still known only by its code name. Comments range from interest in synthesis difficulty and real-world tolerability to skepticism about cross-trial comparisons and hype.

What this discussion establishes

retatrutide passed its first late-stage diabetes trial
UBT251 remains referred to only by its code name
triple agonist may be harder to synthesize than tirzepatide or retatrutide
dropout rates appear low but real-world tolerability data are lacking
no head-to-head studies yet and approval filing has not occurred

Where people disagree

whether retatrutide represents a clear game-changer given differences in trial design and limited safety transparency

Still open

common name for UBT251 if one exists and when or whether it will become widely available

Nothing here is advice.

6 replies · 7 people

BlueBeacon12archiveopening postMar 19

I read about this company's latest medication for managing weight that succeeded in its first major study on diabetes. They're counting on it heavily to build on their existing injectable treatment and the tablet that's in the works. The article was from a business news outlet. I'm wondering about the comparable product from their rival that got bought – the announcement last year only used a code name for it. Anyone have an idea if it's been given a standard name since or if that hasn't happened yet?

Like Same experience Reply

BlueSignal49archiveMar 19

↳ replying to @BlueBeacon12 (opening post)

Thanks for the article! From my knowledge that drug from the competitor still has one of those numbered names for now.

Like Same experience Reply

BrightLantern89archiveMar 19

UBT251

Like Same experience Reply

WryBramble37archiveMar 19

So the competitor is now using Chinese peptides. LoL

Like Same experience Reply

KeenLedger22archiveMar 20

Man this stuff has me hooked! What a wild moment in history to witness haha

Like Same experience Reply

WryHarbour76archiveMar 22

The numbers catch my eye, yet folks seem to be jumping to conclusions too soon. This medication appears strong on paper, though we're matching results from separate studies with varying groups and regimens. That turns the big weight drop claim into something much murkier. While fewer people quit the studies, it's unclear how well folks will handle it outside controlled settings, particularly since it targets multiple routes simultaneously. The maker still hasn't submitted for clearance, which suggests the complete story isn't as simple as announcements imply. Without direct comparisons between options or clearer info on side effects, I remain doubtful about it being a breakthrough as claimed. The multi-target approach holds potential, but plenty of gaps remain in what we understand.

Like Same experience Reply

SteadyCompass64archiveMar 27

↳ replying to @WryHarbour76

Yeah I’m taking tirz too

Like Same experience Reply

Add your experience

If you have tried it, this topic is still open. Sign in to reply — it takes a minute.